BGPT: Author Review: Els Verhoeyen

Explore by Goal

Quick Explanation Copied

Els Verhoeyen — evidence-based author strength snapshot

Based on the provided record, the author’s publication footprint is large and citation-rich, and their work (e.g., BaEV-envelope pseudotyped LV comparisons) shows a recognizable pattern: mechanistic vector-development studies with quantitative transduction/engraftment readouts, plus explicit discussion of limitations and donor/assay variability. Key scientific strength signals include (i) multi-cell-type testing (T/B/NK/HSPCs), (ii) in vivo validation in humanized mice, and (iii) direct comparator vectors (BaEV vs HERV-W) in matched experimental workflows. However, limitations remain: small in vivo group sizes, primary-cell donor heterogeneity, and residual uncertainty about receptor-dependence/generalizability and longer-term safety. These conclusions are conditional on the excerpts/data you supplied.

Long Explanation

Author Review: Els Verhoeyen

Scope of this review (from your provided inputs): (1) publication-year/citation/open-access trends from the provided OpenAlex-like summary, and (2) deep critique of one specific vector-development paper excerpted in your dataset.

Epistemic humility: without full-text access to all works, this review cannot assess experimental quality across the entire portfolio. Where I make claims, I tie them to the provided excerpt(s) and cite the supplied DOI(s).

1) Output & citation trends (from provided year-binned data)

Interpreting these as signals, not proof: year-binned publication and citation counts can be affected by field-wide growth, co-author networks, and citation practices.

2) Deep critique of a supplied portfolio highlight: BaEV pseudotyped LV vs HERV-W

Your dataset provides extracted experimental results and an author conflict-of-interest statement for “Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs” ().

2A) What looks scientifically strong (based on the excerpt)

Direct comparator design: the excerpt frames BaEV-LVs versus HERV-W-LVs as head-to-head, which reduces “hand-wavy” claims and helps attribution to the envelope choice ().
Multi-target relevance: multiple human immune/hematopoietic targets are included (T, B, NK, CD34+ HSPCs), which is important because envelope–receptor usage and cell-state effects often differ strongly across these populations ().
In vivo humanized model validation: the excerpt reports NBSGW mouse engraftment analyses across multiple tissues and a stated engraftment consistency differential (6/6 BaEV recipients vs variability for HERV-W) ().

2B) Scientific concerns / blind spots (what could weaken inference)

Small in vivo sample sizes: the excerpt flags limited in vivo n≈5–6 per group, which increases uncertainty around variability and tail outcomes ().
Primary-cell donor variability: even with matching protocols, “primary cells from donors” can dominate signal variance; the excerpt explicitly notes donor variability as a limitation ().
MOI-asymmetry concern: the excerpt describes HERV-W needing very high MOIs to reach comparable transduction in some populations; this may confound interpretation of intrinsic efficiency versus practical feasibility under different constraints ().
Receptor usage / state dependence not fully resolved: envelope–receptor links (e.g., ASCT-1/ASCT-2 mentioned in the excerpt’s taxonomy) may vary with resting versus stimulated states; the excerpt says receptor-usage variability wasn’t fully dissected for all resting conditions ().
Safety & longer-term outcomes: the excerpt notes long-term safety/off-target effects are not fully addressed, which limits how strongly one can generalize from transduction/engraftment performance to clinical feasibility ().
Conflict-of-interest relevance: the excerpt states the author is an inventor on a patent covering BaEV envelope pseudotyping; this doesn’t invalidate the data, but it increases the need for skepticism about framing, selection of comparisons, and interpretation emphasis ().

2C) Reproducibility-minded critique (what I’d want to see in full text)

Exact replicate structure: how many independent experiments vs technical replicates for each cell donor and MOI condition.
Statistics details: which tests were used for multiple comparisons across cell types, donors, and tissues.
Consistency criteria: how “more reproducible” was quantified (e.g., variance of transduction across donors, not only means).
Safety assays: integration-site/off-target evaluation strategy, persistence, and phenotype stability beyond the engraftment readout.

3) Strength-of-evidence synthesis (conditional on supplied inputs)

Known from provided excerpt:

BaEV-envelope pseudotyped LVs are reported to outperform HERV-W-LVs for transduction across multiple hematopoietic/immune targets, with stronger performance and/or more consistency across contexts ().
In vivo comparisons are included, but sample size and long-term safety limitations are explicitly acknowledged ().

Uncertain / not fully resolved in excerpt:

Whether receptor/state dependence fully explains the advantage (excerpt suggests incomplete receptor-usage dissection for all resting contexts).
Whether observed advantages translate to durable phenotype, persistence, and safety beyond the presented timepoints/readouts.

Confidence level

Moderate confidence for the *directional* claim (BaEV > HERV-W in the described experiments) because the excerpt includes quantitative, multi-cell-type and in vivo context comparisons; confidence is limited by small in vivo n, donor variability, MOI comparability issues, and incomplete long-term safety assessment ().

Relevant BGPT deep-dive shortcuts

Feedback:

Updated: May 02, 2026